Cheney Mao – Chairman & CEO, Viva Biotech, China
Dr Cheney Mao, chairman and CEO of Viva Biotech, shares the extremely unique business model of the company, which started as a highly specialized CRO in 2008, before launching a…
Address: Guilinyang Industrial Development Zone, Haikou, Hainan, China
Tel: 0898-65710069
Hainan Dongfang Dahui Starch Products Co., Ltd. is a national key leading enterprise in agricultural industry which owned the state’s financial investment, integrating cassava cultivation, production , deep-processing, etc, and owning 6 production lines to produce chemical modified starch, drying modified starch, pre-gelatinized modified starch, glutinous rice starch, etc, which supply series of high-quality cassava starch and modified starch products, widely used in the fields of food, paper, textile, feed, construction materials, petroleum, chemical industry, etc.. It has passed Certification of ISO9001-2008 Quality Management System, and HACCP-EC-01 Certification of Food Safety Management System. In 2006, it is honored as National Agricultural Products Processing Demonstration Enterprise by China Agricultural Department. Meanwhile, it is the only manufacture of organic cassava starch in China, which passed the organic certification of Canada, USDA, IFOAM and OFDC organization.
Food Series
Modified starch glue prime
Feed Series
Chemical Building Materials Series
Modified starch glue prime
Petroleum chemicals Series
Dr Cheney Mao, chairman and CEO of Viva Biotech, shares the extremely unique business model of the company, which started as a highly specialized CRO in 2008, before launching a…
Eric Bouteiller outlines the paradigm shift occurring in China around rare diseases and how the country has the potential to lead the global pharmaceutical industry in this vital area. …
Download our latest pharma country report on China here 2019 is a landmark year for China, marking not only the 70th anniversary of the establishment of the People’s Republic…
Dr. Zhengyu Yuan, president & CEO of MicuRx, shares the story of how MicuRx was founded in 2007 to develop new and innovative antimicrobial drugs; their flagship product, contezolid, which…
Mike Braun, partner at Deloitte China, shares his perspectives on the recent China reforms, the strong presence of Deloitte within China as a consulting firm with a DNA in professional…
On 21 September 2019, the China Pharmaceutical International Innovation and Research Development Association (PhIRDA), officially inaugurated the 4th China Biomed International Innovation Conference (CBIIC), at the Suzhou International Convention and…
2009 marks 40 years of China’s liberalization and opening up under then-Premier Deng Xiaoping. Servier China also bears the distinction of having been established that year, celebrating its 40th anniversary…
The meteoric growth of the pharmaceutical industry in China in recent years has seen a host of top Chinese talent return home from studying and working overseas to establish their…
Jin Wang, Partner and Co-leader of the McKinsey China Healthcare Practice, shares the wide-ranging scope of her focus on ‘Big Healthcare’ involving work with healthcare service providers and payers, and pharmaceutical…
China’s healthcare system, which impacts 1.4 billion people, is facing serious capacity issues at all stages of the value chain. Against this backdrop, the country is looking at making wholesale…
Given the undeniably challenging and dynamic China market, most industry stakeholders would agree that the paramount factor behind the success of multinationals’ China affiliates is talent – not only at…
2019 saw Boehringer Ingelheim (BI) veteran Felix Gutsche take up his first country manager role – of a top-three affiliate, no less – after blazing a rather unorthodox path. From…
See our Cookie Privacy Policy Here
